The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation

OncoImmunology

Volumn 6, Issue 1, 2017, Pages

  Routy, Bertrand ^a,b   Letendre, Caroline ^b   Enot, David ^a   Chénard Poirier, Maxime ^c   Mehraj, Vikram ^d   Séguin, Noémie Charbonneau ^b   Guenda, Khaled ^b   Gagnon, Kathia ^b   Woerther, Paul Louis ^a,e   Ghez, David ^a   Lachance, Silvy ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e GRCC   (France)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic stem cell transplantation; Antibiotics; Gut decontamination; Microbiota

Indexed keywords

BUSULFAN; CARBAPENEM; CIPROFLOXACIN; COTRIMAZINE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; LEVOFLOXACIN; MELPHALAN; MOXIFLOXACIN; TOPOTECAN; VANCOMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLERGY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFLAMMATION; INTESTINE FLORA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

EID: 85008223872     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1258506     Document Type: Article

References (37)

1. Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016; 164:337-40; PMID:26824647; http://dx.doi.org/10.1016/j.cell.2016.01.013
2. Garrett WS. Cancer and the microbiota. Science 2015; 348:80-6; PMID:25838377; http://dx.doi.org/10.1126/science.aaa4972
3. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell 2016; 165:276-87; PMID:27058662; http://dx.doi.org/10.1016/j.cell.2016.03.001
4. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107:1581-9 PMID:11413166; http://dx.doi.org/10.1172/JCI12156
5. Zeiser R, Socie G, Blazar BR. Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. Br J Haematol 2016; 175:191-207; PMID:27619472; http://dx.doi.org/10.1111/bjh.14295
6. Chen Y, Zhao Y, Cheng Q, Wu D, Liu H. The role of intestinal microbiota in acute graft-versus-host disease. J Immunol Res 2015; 2015:145859; PMID:26090477; http://dx.doi.org/10.1155/2015/145859
7. van Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst 1977; 58:787-90; PMID:14265[PubMed]
8. Wagemaker G, Heidt PJ, Merchav S, van Bekkum DW. Abrogation of histocompatibility barriers to bone marrow transplantation in rhesus monkeys. In: Baum SD, Ledney GD, Thierfelder S, eds. Experimental Hematology Today. Basel, Switzerland: Karger, 1982
9. Whangbo J, Ritz J, Bhatt A. Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2016; PMID:27526283; http://dx.doi.org/10.1038/bmt.2016.206
10. Kimura S, Akahoshi Y, Nakano H, Ugai T, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect 2014; 69:13-25; PMID:24583063; http://dx.doi.org/10.1016/j.jinf.2014.02.013
11. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; http://dx.doi.org/10.1126/science.1240537
12. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342:967-70; PMID:24264989; http://dx.doi.org/10.1126/science.1240527
13. Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci Transl Med 2015; 7:271; PMID:25609166; http://dx.doi.org/10.1126/scitranslmed.3010473
14. Xu X, Zhang X. Effects of cyclophosphamide on immune system and gut microbiota in mice. Microbiol Res 2015; 171:97-106; PMID:25553830; http://dx.doi.org/10.1016/j.micres.2014.11.002
15. Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L, No D, Gobourne A, Viale A, Dahi PB et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124:1174-82; PMID:24939656; http://dx.doi.org/10.1182/blood-2014-02-554725
16. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, Littmann ER, Ling L, Gobourne AC, Miller LC et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21:1373-83; PMID:25977230; http://dx.doi.org/10.1016/j.bbmt.2015.04.016
17. Tsirigotis PD, Resnick IB, Or R, Elad S, Zilberman I, Yoffe L, Levovic A, Miron S, Gesundheit B, Slavin S et al. Post-hematopoietic stem cell transplantion immune-mediated cytopenias. Immunotherapy 2009; 1:39-47; PMID:20635972; http://dx.doi.org/10.2217/1750743X.1.1.39
18. Han DK, Baek HJ, Kim SY, Hwang TJ, Kook H. Implication of early lymphocyte recovery after allogeneic hematopoietic stem cell transplantation in children with leukemia. Yonsei Med J 2013; 54:62-70; PMID:23225800; http://dx.doi.org/10.3349/ymj.2013.54.1.62
19. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1:56-66; PMID:18043614; http://dx.doi.org/10.1038/ismej.2007.3
20. Willing BP, Russell SL, Finlay BB. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat Rev Microbiol 2011; 9:233-43; PMID:21358670; http://dx.doi.org/10.1038/nrmicro2536
21. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science 2016; 352:544-5; PMID:27126037; http://dx.doi.org/10.1126/science.aad9358
22. Taguer M, Maurice CF. The complex interplay of diet, xenobiotics, and microbial metabolism in the gut: Implications for clinical outcomes. Clin Pharmacol Ther 2016; 99:588-99; PMID:26950037; http://dx.doi.org/10.1002/cpt.366
23. Heidegger S, van den Brink MR, Haas T, Poeck H. The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation. Front Immunol 2014; 5:337; PMID:25101080; http://dx.doi.org/10.3389/fimmu.2014.00337
24. Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 2016; 8:339-71; PMID:27194729; http://dx.doi.org/10.1126/scitranslmed.aaf2311
25. Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med 2016; 22:458-78; PMID:27178527; http://dx.doi.org/10.1016/j.molmed.2016.04.003
26. Romick-Rosendale LE, Goodpaster AM, Hanwright PJ, Patel NB, Wheeler ET, Chona DL, Kennedy MA. NMR-based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad-spectrum antibiotic enrofloxacin (Baytril). Magn Reson Chem 2009; 47 (Suppl 1):S36-46; PMID:19768747; http://dx.doi.org/10.1002/mrc.2511
27. Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol 2004; 70:6113-22; http://dx.doi.org/10.1128/AEM.70.10.6113-6122.2004
28. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576-83; PMID:17785583; http://dx.doi.org/10.1182/blood-2007-06-097386
29. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119:296-307; PMID:22010102; http://dx.doi.org/10.1182/blood-2011-06-364265
30. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487-96; PMID:23075175; http://dx.doi.org/10.1056/NEJMoa1203517
31. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369:529-39; PMID:23924003; http://dx.doi.org/10.1056/NEJMoa1213299
32. Boga S, Alkim H, Koksal AR, Ozagari AA, Bayram M, Tekin Neijmann S, Sen I, Alkim C. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J Invest Med 2016; 64:1016-24; PMID:27001944; http://dx.doi.org/10.1136/jim-2016-000062
33. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014; 513:564-8; PMID:25043027; http://dx.doi.org/10.1038/nature13577
34. Mehraj V, Jenabian MA, Ponte R, Lebouche B, Costiniuk C, Thomas R, Baril JG, LeBlanc R, Cox J, Tremblay C et al. The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS 2016; 30:1617-27; PMID:27045377; http://dx.doi.org/10.1097/QAD.0000000000001105
35. Mehraj V, Ponte R, Routy JP. The dynamic role of the IL-33/ST2 axis in chronic viral-infections: alarming and adjuvanting the immune response. EBioMedicine 2016; 9:37-44; PMID:27397514; http://dx.doi.org/10.1016/j.ebiom.2016.06.047
36. Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 2015; 42:1005-19; PMID:26084021; http://dx.doi.org/10.1016/j.immuni.2015.06.006
37. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM. Interleukin-33 and interferon-gamma counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity 2015; 43:161-74; PMID:26092469; http://dx.doi.org/10.1016/j.immuni.2015.05.019